July + August 2011 Newsletter Now Available

Top stories from TTO's July + August newsletter:

Perspective: Major Funding Milestones for CU Licensees and Companies
In the last few weeks, several CU licensees and partner companies achieved significant financing milestones, including VC funding rounds, acquisitions and grants. This trend fits with a statewide increase in investment in the second quarter of 2011; and while one swallow doesn't make a summer, we're hopeful that this trend will continue through 2011, enabling our partner companies to bring CU technologies closer to the market. (See the full list of recent financings in the newsletter.)

TTO Announces August 15 Deadline for BDEG Project Summaries
Under the State of Colorado's Bioscience Discovery and Evaluation Grant (BDEG) Program, CU researchers are eligible for awards of $50,000 to $200,000 for commercial proof-of-concept (POC) work; eligible fields include therapeutics, diagnostics, medical devices, platform technologies, and biofuels. Interested researchers must submit a short Project Summary to TTO by August 15, 2011, as well as an Invention Disclosure if one is not already in place. The deadline for the application itself is September 9, 2011. Applications and more information are available online. 

Heidelberg Instruments to Develop CU Nanotech Platform
Heidelberg Instruments GmbH (Heidelberg, Germany) and the University of Colorado recently completed an exclusive option agreement for a CU technique that shrinks the circuitry of nano-devices, enabling the creation of smaller computer chips and other nanodevices. (Read full press release.)

TTO Welcomes New Director, BioPharma Alliances at CU
TTO is pleased to welcome Dr. Laura Simon, Director of the new Office of BioPharma Alliances for CU Denver and the Anschutz Medical Campus. Laura will serve as a liaison between faculty researchers and biotechnology, pharmaceutical and device companies. The Office of BioPharma Alliances is a campus-supported resource for research programs interested in strategic (big picture, multi-year, large dollar) relationships with biomedical enterprises, and is part of CU Denver's Office of the Vice Chancellor for Research. (Read the full profile.)

Read the full newsletter, or sign up to receive a monthly email update.